Ozurdex
·
- Prescription status not stated
- Eyes and ears
- Active substance
- Dexamethasone
- Used in
- Eyes and ears
- Made by
- AbbVie Deutschland GmbH & Co. KG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO). Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis. Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
From the official label · 2026-09-30 · European Medicines Agency
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (dexamethasone). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Dexamethasone is a corticosteroid with anti-inflammatory effects and low mineralocorticoid activity.
The precise mechanism of action in multiple myeloma is unknown.
Dexamethasone is metabolized by CYP3A4.
Less than 10% of dexamethasone is excreted in the urine.
Effect of Food A high-fat, high-calorie (total 800-1000 calories: approximately 60% from fat, 25% from carbohydrate and 15% from protein) meal had no effect on AUC inf and decreased C max by 23% of a single 20 mg dose of HEMADY.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-09
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
BulgariaNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | AbbVie Deutschland GmbH & Co. KG |
|---|---|
| Active substance | Dexamethasone |
| Used in | Eyes and ears |
| Classification | S01BA01 · Eyes and ears |
| Authorised on | 2010-07-26 |
| Last updated by the regulator | 2026-05-29 |
| EMA product number | EMEA/H/C/001140 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.